ReviewCurrent opinion in rheumatology2016
Molecular stratification and precision medicine in systemic sclerosis from genomic and proteomic data.
Review in Current opinion in rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Computed tomography-based radiomics decodes prognostic and molecular differences in interstitial lung disease related to systemic sclerosis.The European respiratory journal · 2022Article
- Insights Into Systemic Sclerosis from Gene Expression Profiling.Current treatment options in rheumatology · 2021Article
- Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement.Annals of the rheumatic diseases · 2021Article
- Molecular "omic" signatures in systemic sclerosis.European journal of rheumatology · 2020Review
- Emerging Roles of Matricellular Proteins in Systemic Sclerosis.International journal of molecular sciences · 2020Review
- Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis.Arthritis & rheumatology (Hoboken, N.J.) · 2020Article
- Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile.Annals of the rheumatic diseases · 2020Article
- The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib.Journal of scleroderma and related disorders · 2020Article
- Recent advances steer the future of systemic sclerosis toward precision medicine.Clinical rheumatology · 2020Article
- Shared and distinct mechanisms of fibrosis.Nature reviews. Rheumatology · 2019Review
- Biomarkers in systemic sclerosis.Current opinion in rheumatology · 2019Review
- A Machine Learning Classifier for Assigning Individual Patients With Systemic Sclerosis to Intrinsic Molecular Subsets.Arthritis & rheumatology (Hoboken, N.J.) · 2019Article
- Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis.Translational research : the journal of laboratory and clinical medicine · 2019Review
- The mechanistic implications of gene expression studies in SSc: Insights from Systems Biology.Current treatment options in rheumatology · 2017Article
- Current perspectives on the immunopathogenesis of systemic sclerosis.ImmunoTargets and therapy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purpose of reviewThe goal of this review is to summarize recent advances into the pathogenesis and treatment of systemic sclerosis (SSc) from genomic and proteomic studies. RECENT
findingsIntrinsic gene expression-driven molecular subtypes of SSc are reproducible across three independent datasets. These subsets are a consistent feature of SSc and are found in multiple end-target tissues, such as skin and esophagus. Intrinsic subsets as well as baseline levels of molecular target pathways are potentially predictive of clinical response to specific therapeutics, based on three recent clinical trials. A gene expression-based biomarker of modified Rodnan skin score, a measure of SSc skin severity, can be used as a surrogate outcome metric and has been validated in a recent trial. Proteome analyses have identified novel biomarkers of SSc that correlate with SSc clinical phenotypes. SUMMARY: Integrating intrinsic gene expression subset data, baseline molecular pathway information, and serum biomarkers along with surrogate measures of modified Rodnan skin score provides molecular context in SSc clinical trials. With validation, these approaches could be used to match patients with the therapies from which they are most likely to benefit and thus increase the likelihood of clinical improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.